NEUGEBOREN EDWARD
SEC insider (Form 3/4/5 filer). CIK 0001320873. Director at Grace Therapeutics, Inc. (GRCE) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Sep 17, 2026. Located in PRINCETON, NJ.
Companies NEUGEBOREN EDWARD has filed insider reports for
- Grace Therapeutics, Inc. (GRCE): Director
- Matinas BioPharma Holdings, Inc. (MTNB): Director
NEUGEBOREN EDWARD
CIK: 0001320873
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 17, 2026GRCE
Grace Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
12.2K shares- - Jan 8, 2026GRCE
Grace Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
10K shares- - May 9, 2025GRCE
Grace Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
10K shares- - Apr 30, 2025MTNB
Matinas BioPharma Holdings, Inc.
AwardDirectStock Option (right to Buy)
11.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 17, 2026 |  GRCE Grace Therapeutics, Inc. | Award Stock Option (Right to Buy) | 12,200 | - | - | Direct |
| Jan 8, 2026 | GRCE Grace Therapeutics, Inc. | Award Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| May 9, 2025 | GRCE Grace Therapeutics, Inc. | Award Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Apr 30, 2025 |  MTNB Matinas BioPharma Holdings, Inc. | Award Stock Option (right to Buy) | 11,600 | - | - | Direct |
1-4 of 4 transactions